EVAX Stock Analysis: Buy, Sell, or Hold?
EVAX - Evaxion A/S American Depositary Share
$3.41
0.21 (6.56%)
▲
5d:
+8.6%
30d:
-9.07%
90d:
-13.45%
BUY
HIGH Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 20, 2026
Get Alerted When EVAX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: EVAX shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: EVAX shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: EVAX is currently trading at $3.41, which is considered fair relative to its 30-day fair value range of $3.24 to $3.87. The stock's valuation (Forward PE: 85.2) is in line with its historical norms (87.3). Remarkably, the market is currently pricing in an annual earnings decline of 0.8% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, EVAX is in a uptrend. The price is currently testing key support at $3.42. A bounce from this level would confirm strength, while a break below could signal further downside. The stock is showing strong short-term momentum, up 6.6% recently.
Market Sentiment: EVAX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $11.25 (+229.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, EVAX is in a uptrend. The price is currently testing key support at $3.42. A bounce from this level would confirm strength, while a break below could signal further downside. The stock is showing strong short-term momentum, up 6.6% recently.
Market Sentiment: EVAX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $11.25 (+229.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$3.24 -
$3.87
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
88.1%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+6.6%)
- BULLISH: Trading 229.9% below Wall St target ($11.25)
Trading Range Analysis
30-Day Trading Range
$3.24 -
$3.87
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$3.42
Resistance Level
$4.23
Current Trend
Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
85.25
Wall Street Target
$11.25
(+229.9%)
Revenue Growth (YoY)
-100.0%
Profit Margin
-129.6%
Valuation Discount vs History
-0.8% cheaper
PE vs Historical
85.3 vs 87.3
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-0.8%
(market-implied from PE analysis)
1-Year Target
$3.38
(-1%)
2-Year Target
$3.36
(-2%)
3-Year Target
$3.33
(-2%)
3-Yr Target (if PE normalizes)
(PE: 85→87)
$3.41
(0%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 85.2 to 87.3
Stabilization Target:
$3.49
(+2.4%)
PE Expansion Potential:
+2.4%
Share & Embed Analysis
Last updated: July 02, 2026 10:41 PM ET
Data refreshes hourly during market hours. Next update: 11:41 PM
Data refreshes hourly during market hours. Next update: 11:41 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EVAX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$436 | 64 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 56 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 62 BUY |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$257 | 61 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$31 | 58 HOLD |